| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
Departments of 1 Molecular and Cellular Oncology and 2 Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas and 3 Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Science Center, New Orleans, Louisiana
Requests for reprints: Rakesh Kumar, Department of Molecular and Cellular Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 108, Houston, TX 77030. Phone: 713-745-3558; Fax: 713-745-3792; E-mail: rkumar{at}mdanderson.org or Ratna K. Vadlamudi, Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Science Center, 533 Bolivar Street, New Orleans, LA 70112; E-mail: rvadla{at}lsuhsc.edu.
It is increasingly accepted that steroidal receptor coregulators may also function in the cytoplasmic compartment. Proline-, glutamic acid, and leucine-rich protein-1 (PELP1) is a novel coregulator that plays a role in both the genomic and extranuclear actions of estrogen receptors (ER) in hormonally responsive tissues. In this study using breast tumor arrays, we found that PELP1 was localized only in the cytoplasm in 58% of the PELP1-positive breast tumors. To help explain the significance of the cytoplasmic localization of PELP1 in human breast tumors, we created a mutant protein that was expressed only in the cytoplasm (PELP1-cyto) and then generated a model system wherein MCF-7 breast cancer cells were engineered to specifically express this mutant. We found that PELP1-cyto cells were hypersensitive to estrogen but resistant to tamoxifen. PELP1-cyto cells, but not parental MCF-7 cells, formed xenograft tumors in nude mice. In addition, PELP1-cyto cells exhibited increased association of PELP1 with Src, enhanced mitogen-activated protein kinase (MAPK) activation, and constitutive activation of AKT. The altered localization of PELP1 was sufficient to trigger the interaction of PELP1 with the p85 subunit of phosphatidylinositol-3-kinase (PI3K), leading to PI3K activation. In addition, PELP1 interacted with epidermal growth factor receptors and participated in growth factormediated ER transactivation functions. Our results suggest that the altered localization of PELP1 modulates sensitivity to antiestrogens, potentiates tumorigenicity, presumably via the stimulation of extranuclear estrogen responses, such as the activation of MAPK and AKT, and also enhance cross-regulation of ER transactivation activity by growth factors.
This article has been cited by other articles:
![]() |
R. Kumar, H. Zhang, C. Holm, R. K. Vadlamudi, G. Landberg, and S. K. Rayala Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Clin. Cancer Res., June 15, 2009; 15(12): 4123 - 4130. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Baker Jr., J. H. Ostrander, S. Lem, G. Broadwater, G. R. Bean, N. C. D'Amato, V. K. Goldenberg, C. Rowell, C. Ibarra-Drendall, T. Grant, et al. ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1884 - 1890. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lombardi, G. Castoria, A. Migliaccio, M. V. Barone, R. Di Stasio, A. Ciociola, D. Bottero, H. Yamaguchi, E. Appella, and F. Auricchio Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells J. Cell Biol., July 28, 2008; 182(2): 327 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dimple, S. S. Nair, R. Rajhans, P. R. Pitcheswara, J. Liu, S. Balasenthil, X.-F. Le, M. E. Burow, N. Auersperg, R. R. Tekmal, et al. Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis Cancer Res., June 15, 2008; 68(12): 4902 - 4909. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Nagpal, S. Nair, D. Chakravarty, R. Rajhans, S. Pothana, D. W. Brann, R. R. Tekmal, and R. K. Vadlamudi Growth Factor Regulation of Estrogen Receptor Coregulator PELP1 Functions via Protein Kinase A Pathway Mol. Cancer Res., May 1, 2008; 6(5): 851 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rajhans, H. B. Nair, S. S. Nair, V. Cortez, K. Ikuko, N. B. Kirma, D. Zhou, A. E. Holden, D. W Brann, S. Chen, et al. Modulation of in Situ Estrogen Synthesis by Proline-, Glutamic Acid-, and Leucine-Rich Protein-1: Potential Estrogen Receptor Autocrine Signaling Loop in Breast Cancer Cells Mol. Endocrinol., March 1, 2008; 22(3): 649 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F.G Lucas, E. R Siu, C. A Esteves, H. P Monteiro, C. A Oliveira, C. S Porto, and M. F. M Lazari 17Beta-Estradiol Induces the Translocation of the Estrogen Receptors ESR1 and ESR2 to the Cell Membrane, MAPK3/1 Phosphorylation and Proliferation of Cultured Immature Rat Sertoli Cells Biol Reprod, January 1, 2008; 78(1): 101 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohshiro, S. K. Rayala, S. Kondo, A. Gaur, R. K. Vadlamudi, A. K. El-Naggar, and R. Kumar Identifying the Estrogen Receptor Coactivator PELP1 in Autophagosomes Cancer Res., September 1, 2007; 67(17): 8164 - 8171. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Manavathi, S. K. Rayala, and R. Kumar Phosphorylation-dependent Regulation of Stability and Transforming Potential of ETS Transcriptional Factor ESE-1 by p21-activated Kinase 1 J. Biol. Chem., July 6, 2007; 282(27): 19820 - 19830. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rajhans, S. Nair, A. H. Holden, R. Kumar, R. R. Tekmal, and R. K. Vadlamudi Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid-, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen Receptor Cancer Res., June 1, 2007; 67(11): 5505 - 5512. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Greger, N. Fursov, N. Cooch, S. McLarney, L. P. Freedman, D. P. Edwards, and B. J. Cheskis Phosphorylation of MNAR Promotes Estrogen Activation of Phosphatidylinositol 3-Kinase Mol. Cell. Biol., March 1, 2007; 27(5): 1904 - 1913. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Nair, Z. Guo, J. M. Mueller, S. Koochekpour, Y. Qiu, R. R. Tekmal, R. Schule, H.-J. Kung, R. Kumar, and R. K. Vadlamudi Proline-, Glutamic Acid-, and Leucine-Rich Protein-1/Modulator of Nongenomic Activity of Estrogen Receptor Enhances Androgen Receptor Functions through LIM-Only Coactivator, Four-and-a-Half LIM-Only Protein 2 Mol. Endocrinol., March 1, 2007; 21(3): 613 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Manavathi, F. Acconcia, S. K. Rayala, and R. Kumar An inherent role of microtubule network in the action of nuclear receptor PNAS, October 24, 2006; 103(43): 15981 - 15986. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohshiro, S. K. Rayala, M. D. Williams, R. Kumar, and A. K. El-Naggar Biological Role of Estrogen Receptor {beta} in Salivary Gland Adenocarcinoma Cells. Clin. Cancer Res., October 15, 2006; 12(20): 5994 - 5999. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vijayanathan, S. Venkiteswaran, S. K. Nair, A. Verma, T.J. Thomas, B. T. Zhu, and T. Thomas Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2038 - 2048. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Rayala, P. d. Hollander, S. Balasenthil, P. R. Molli, A. J. Bean, R. K. Vadlamudi, R.-A. Wang, and R. Kumar Hepatocyte Growth Factor-regulated Tyrosine Kinase Substrate (HRS) Interacts with PELP1 and Activates MAPK J. Biol. Chem., February 17, 2006; 281(7): 4395 - 4403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Rayala, J. Mascarenhas, R. K. Vadlamudi, and R. Kumar Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol. Cancer Ther., February 1, 2006; 5(2): 230 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Gururaj, S. K. Rayala, R. K. Vadlamudi, and R. Kumar Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations Clin. Cancer Res., February 1, 2006; 12(3): 1001s - 1007s. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |